Date: 2012-09-10
Type of information: Preclinical data
phase: preclinical
Announcement: preclinical data
Company: Silence Therapeutics (UK)
Product: Atu111
Action
mechanism: Atu111 targets the endothelial expression of Angiopoietin-2 (Ang-2), an antagonistic ligand of Tie-2 signalling, which is implicated in progressing endothelial dysfunction in the context of disease pathogenesis for acute lung injury or sepsis. The product uses the DACC drug delivery system which is a lipid-based formulation which is designed to tackle lung-specific diseases. Delivered by blood infusion, the DACC particles become trapped in the small blood vessels of the lungs.
Disease: acute lung injury (ALI)
Therapeutic area: Lung diseases
Country:
Trial details:
Latest
news: Silence Therapeutics, aRNA interference (RNAi) therapeutics company, has announced that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.The study, which evaluated the use of Atu111 in a preclinical Streptococcus pneumoniae model of acute lung injury, was conducted by Ricerca Biosciences, a US-based clinical research organisation. The trial demonstrated a 90% survival benefit with the use of Atu111 in the presence of antibiotics when compared to an untreated control cohort. By contrast, antibiotic therapy alone achieves only a 20% survival benefit over untreated.To further evaluate the findings, Silence has started a research alliance with the laboratory of Prof. Dr. med. Hermann Haller, Director of Nephrology and Chairman of the Department of Internal Medicine at the Medizinische Hochschule Hannover MHH (Hannover Medical School, Germany) to evaluate the therapeutic potential of Atu111 in preclinical models for acute lung injury and sepsis. In collaboration with Dr. Sascha David, lead investigator in this project, Atu111, a novel RNAi therapeutic drug candidate based on Silence´s proprietary DACC formulation will be investigated in various pre-clinical models assessing the therapeutic value of Atu111 treatment on inhibiting progression of acute lung injury or sepsis.
A first proof-of-concept with Atu111 in a model for septic/systemic shock revealed superior survival in the Atu111 cohort over an unrelated control formulation. This initial result laid the foundation for the projected systematic investigations addressing the full pharmacological and pharmacodynamic understanding of Atu111 in models of this devastating disease.
